Reuters -- AstraZeneca (AZN.L) expects double-digit growth in emerging markets, the new battleground for Big Pharma as sales in Western markets stall, but said on Tuesday it would be much more selective than some of its rivals.
Reuters -- AstraZeneca (AZN.L) expects double-digit growth in emerging markets, the new battleground for Big Pharma as sales in Western markets stall, but said on Tuesday it would be much more selective than some of its rivals.
